Mercury Biopharmaceutical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Income	-43.41	-43.82	-31.25	-5.31	-0.21	-0.2
Depreciation & Amortization	5.6	4.07	2.75	0.97	-	-
Stock-Based Compensation	1.57	1.82	1.13	-	-	-
Other Operating Activities	-0.04	0.29	-0.02	-	-	-
Change in Accounts Payable	3.18	0.64	4.86	0.9	-	0.01
Change in Unearned Revenue	5.73	0.44	-	-	-	-
Change in Other Net Operating Assets	-1.3	-5.6	-3.31	-1.34	-0.01	-0
Operating Cash Flow	-28.7	-42.15	-25.84	-4.78	-0.22	-0.2
Capital Expenditures	-11.86	-12.93	-68.51	-6.98	-	-
Sale (Purchase) of Intangibles	-0.72	-0.65	-0.14	-0.53	-	-
Investment in Securities	174.96	-176.08	-108.7	-	-	-
Other Investing Activities	-2.54	-4.79	-8.04	-0.51	-	-
Investing Cash Flow	159.83	-194.44	-185.4	-8.02	-	-
Long-Term Debt Issued	-	-	41.6	-	-	-
Long-Term Debt Repaid	-	-1.07	-0.99	-0.39	-	-
Net Debt Issued (Repaid)	-1.11	-1.07	40.61	-0.39	-	-
Issuance of Common Stock	0.3	250	200	15.97	-	-
Other Financing Activities	-	-	-	-0.3	0.15	0.35
Financing Cash Flow	-47.86	248.93	240.61	15.28	0.15	0.35
Foreign Exchange Rate Adjustments	-0.01	0.01	-	-	-	-
Net Cash Flow	83.27	12.36	29.38	2.48	-0.07	0.15
Free Cash Flow	-40.56	-55.07	-94.35	-11.77	-0.22	-0.2
Free Cash Flow Margin	-705.41%	-5331.17%	-3520.60%	-	-	-
Free Cash Flow Per Share	-0.10	-0.13	-0.25	-0.04	-0.00	-
Cash Interest Paid	0.74	0.71	0.4	0.01	-	-
Cash Income Tax Paid	0.33	0.21	0.02	-	-	-
Levered Free Cash Flow	-27.32	-41.24	-82.81	-10.3	-0.14	-
Unlevered Free Cash Flow	-26.86	-40.8	-82.56	-10.3	-0.14	-
Change in Net Working Capital	-7.82	4.57	-1.53	0.45	0.01	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.